YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The pharmaceutical market is currently defined by a race to replace aging blockbusters with next-generation therapies. Deciding whether to buy AbbVie Inc (NYSE:ABBV) or Eli Lilly and Co (NYSE:LLY) requires weighing different growth engines…
On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveraging OmniAb's specialized antibody discover…
EMERYVILLE, Calif., August 26, 2026--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management's participation…
[Stock market Exchanges Volume Leaders Digital Tableau interface background] bestsale Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impa…
This article first appeared on GuruFocus. OmniAb Inc. (OABI, Financials) shares soared almost 18% in premarket trade after the company raised its cash forecast for 2026 on the back of recent license and business-development agreements.The…
OmniAb (OABI) unveiled a partnership with Eli Lilly (LLY) on a new ion-channel drug discovery program, while raising its fiscal 2026 cash and cash equivalents guidance. Shares of OmniAb jumped over 11%, with intraday trading volume rising…
EMERYVILLE, Calif., August 17, 2026--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Financial Officer - Kurt Gustafson President and Chief Executive Officer - Matthew Foehr Chief Operating Officer - Amechi Nwachuku Full Conf…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Financial Officer - Kurt GustafsonPresident and Chief Executive Officer - Matthew FoehrChief Operating Officer - Amechi Nwachuku TAKEAWAYS R…
This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points OmniAb Inc (NASDAQ:OABI) reported a strong second…
EMERYVILLE, Calif., July 13, 2026--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachu…
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company's main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA's main share of investments to ha…
OmniAb, Inc. (NASDAQ:OABI) is one of the Best Small-Cap Growth Stocks to Invest In Now. The stock has gained more than 38% over the past 6 months and around 74% since the release of its fiscal Q1 2026 earnings and business update. The com…
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) is one of the best up and coming stocks on our list. TheFly reported on June 16 that JPMorgan upgraded C…
OmniAb logo Key Points Interested in OmniAb, Inc.? Here are five stocks we like better. OmniAb reported Q1 revenue of $14.4M (vs. $4.2M a year ago) largely driven by milestone revenue, narrowed its net loss to $7.7M, and has raised guidanc…
USANA Health Sciences (USNA) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurrin…
Image source: The Motley Fool. Date March 4, 2026, at 4:30 p.m. ET Call participants President and Chief Executive Officer — Matthew W. FoehrChief Financial Officer — Kurt A. Gustafson Takeaways Active partners -- Reached 107 by year-end,…
OmniAb logo Key Points OmniAb finished 2025 with 107 partners and 407 active programs, adding a net 44 programs during the year; management said >98% of programs include contracted future economics and the portfolio carries >$3 billion in…
Earnings Call Insights: OmniAb, Inc. (OABI) Q3 2025 MANAGEMENT VIEW * CEO Matthew Foehr reported continued strong deal flow in the third quarter with new program additions for 2025 already matching the total from all of 2024. He highlighte…
OmniAb (NASDAQ:OABI [https://seekingalpha.com/symbol/OABI]) has entered into a definitive agreement for a private placement [https://seekingalpha.com/pr/20209816-omniab-announces-30-million-private-placement] of its common stock to raise a…
OmniAb Inc. (NASDAQ:OABI) presented its second-quarter 2025 financial results and business update on August 6, revealing a company experiencing robust partner and program growth despite financial challenges. The antibody discovery platform…
As the U.S. stock market rebounds from recent fluctuations, investors are closely monitoring earnings reports and trade developments. Amid this backdrop, penny stocks remain an intriguing investment area for those seeking potential growth…
Total Revenue: $7.6 million for Q2 2024, compared to $6.9 million in the prior year quarter. Service Revenue: Included an accelerated $1.3 million due to the discontinuation of the GSK small molecule ion channel program. R&D Expense: Relat…
While your typical financial advisor will likely direct you to focus on established blue chips to boost your holdings, few other compelling options exist other than powerful small-cap stocks. To be 100% clear, entities that offer significa…
Generally speaking, you get what you pay for, which should be a warning for speculating on low-priced securities, even if they’re labeled the best cheap stocks under $5. Yes, I’m already working against my own thesis. However, it’s very im…
If Warren Buffett was your financial advisor, he might steer you toward reliable blue-chip investments, not wildly speculative stocks to buy now. Put another way, you’re probably not going to find these enterprises listed among the holding…
In this piece, we will take a look at the ten best small-cap growth stocks to buy now. For more stocks, head on over to 5 Best Small-Cap Growth Stocks to Buy Now. Every day, countless stocks see their values rise and fall on the market. Da…
Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can’t just introduce health-related products directly to the market. Instead, they must undergo inten…
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesse…
For investors, the stock market is always a game of risk and reward, and no segment exemplifies that better than the penny stocks. Defined as stocks trading at a price of less than $5, the pennies bring an ultra-low cost of entry to the ta…
Ligand Pharmaceuticals Incorporated LGND reported fourth-quarter 2022 adjusted diluted earnings of $1.36 per share from continuing operations, which beat the Zacks Consensus Estimate and our estimate of $1.23 per share. The company had rep…
Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting Quatramers™ combined with OmniTaur™-derived Picobodies™, the lead program, HSB-1940,…
Provides Executive Leadership Update SAN DIEGO, November 01, 2022--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the company has completed the expected tax-free spin-off of its OmniAb antibody discovery busi…